Novel nasolacrimal dacryocystorhinostomy combined with fluticasone propionate for the treatment of chronic dacryocystitis
10.3980/j.issn.1672-5123.2024.8.29
- VernacularTitle:新型鼻腔泪囊吻合术联合丙酸氟替卡松治疗慢性泪囊炎
- Author:
Mu QIN
1
,
2
,
3
;
Zhenhua DAI
1
,
2
,
3
;
Shaoying FENG
1
,
2
,
3
;
Shiqi LEI
1
,
2
,
3
;
Guanxiong LEI
1
,
2
,
3
;
Jiasheng YI
1
,
2
,
3
Author Information
1. Affiliated Hospital of Xiangnan University
2. Chenzhou Lacrimal Minimally Invasive Diagnosis and Treatment Technology R&
3. D Center, Chenzhou 423000, Hunan Province, China
- Publication Type:Journal Article
- Keywords:
novel dacryocystorhinostomy;
fluticasone propionate;
chronic dacryocystitis;
visual acuity;
quality of life;
recurrence rate
- From:
International Eye Science
2024;24(8):1332-1335
- CountryChina
- Language:Chinese
-
Abstract:
AIM: To investigate the effect of a new type of rhinodacryocystostomy combined with fluticasone propionate on patients with chronic dacryocystitis.METHODS: A total of 100 patients(100 eyes)with chronic dacryocystitis who admitted to our hospital between January 2021 and December 2022 were enrolled in the prospective study. The patients in the study were divided into a control group(n=50)and an observation group(n=50)based on their admission order and number. Patients in the control group were treated with novel rhinodacryocystostomy, while patients in the observation group were treated with a new type of rhinodacryocystostomy combined with fluticasone propionate. The preoperative and postoperative best corrected visual acuity(BCVA), quality of life score, and recurrence of chronic dacryocystitis were compared between the two groups of patients.RESULTS: All patients completed the postoperative 6 mo follow-up, and the total effective rate of patients in the observation group was better than that of patients in the control group(98% vs 84%, P=0.001). There was no significant difference in preoperative and postoperative BCVA between the two groups(P>0.05). Preoperatively, there was no significant difference in the quality of life scores between the two groups of patients(P>0.05); At 6 mo postoperatively, the quality of life scores of patients in the control group, including physical function, psychological function, social function, and material life status, were lower than those in the observation group(all P<0.001). There were 9 recurrences in the control group(18%)and 1 in the observation group(2%), and there was statistical significance in the postoperative recurrence rate between the two groups(χ2=-2.739, P=0.001).CONCLUSION: The new type of rhinodacryocystostomy combined with fluticasone propionate treatment for chronic dacryocystitis patients has a good therapeutic effect, can improve the quality of life of patients, and reduce the probability of disease recurrence.
